{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004166","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.938604+00:00","generated_at":"2026-06-04T06:13:30.983403+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroBo reports FY 2023 net loss $12.5M; cash $22.4M; DA-1726 Phase 1 to dose Q2 2024","bullets":["Net loss $12.5M ($2.46 per share) vs $14.0M in FY 2022; R&D spend rose to $9.2M.","Cash $22.4M as of Dec. 31, 2023, expected to fund operations into Q4 2024.","DA-1726 Phase 1 obesity trial: first site IRB approved; first patient dosing expected Q2 2024.","DA-1241 Phase 2a MASH trial: SRC approval to continue; full data expected H2 2024.","Marshall Woodworth appointed permanent CFO; company regained Nasdaq compliance after reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004166","json":"https://secwatch.observer/filing/0001558370-24-004166.json","markdown":"https://secwatch.observer/filing/0001558370-24-004166.md","text":"https://secwatch.observer/filing/0001558370-24-004166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/0001558370-24-004166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/nrbo-20240328x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:13:30.983403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c98df9d88304ad04b3a41247fc1a7e7ee73da02","claim":"MetaVia Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024004166/0001558370-24-004166-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}